Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. The company leverages its deep understanding of integrin biology, medicinal chemistry, and translational medicine to create a proprietary drug discovery platform. This platform supports the development of treatments for solid tumors and other diseases by targeting integrin-mediated pathways.
Pliant Therapeutics generates revenue…
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. The company leverages its deep understanding of integrin biology, medicinal chemistry, and translational medicine to create a proprietary drug discovery platform. This platform supports the development of treatments for solid tumors and other diseases by targeting integrin-mediated pathways.
Pliant Therapeutics generates revenue primarily through the advancement and potential commercialization of its product candidates, with no current product sales reported. The company's lead candidate, PLN-101095, is an oral, small molecule dual inhibitor of αvβ8 and αvβ1 integrins being developed for solid tumors resistant to immune checkpoint inhibitors. Revenue is expected to arise from future licensing agreements, partnerships, or product sales upon regulatory approval and commercialization of its pipeline candidates.
The company operates through the following segments:
- Integrin-Targeted Therapeutics: This segment focuses on the discovery and development of small molecule inhibitors targeting specific integrin subtypes to modulate disease pathways. The lead program, PLN-101095, is designed to inhibit αvβ8 and αvβ1 integrins to sensitize tumors to checkpoint inhibitors in solid tumors. The segment also includes Bexotegrast, which was previously developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis but has been discontinued in IPF development.
- Proprietary Drug Discovery Platform: This segment encompasses the company's core technology, including a proprietary library of over 15,000 integrin binding molecules. The platform utilizes a comprehensive screening assay system and an advanced live human tissue program to identify and validate targets. It supports the development of integrin-based drug delivery systems, including siRNA delivery to skeletal muscle cells, adipocytes, and renal cells for various disease applications.
Pliant Therapeutics operates in the highly competitive biotechnology and biopharmaceutical industry, specifically within the integrin-targeted therapeutics niche. The company faces competition from large pharmaceutical firms such as AbbVie, Roche/Genentech, Pfizer, and Incyte, as well as specialized biotech companies including Bicara Therapeutics, Corbus Pharmaceuticals, IO Biotech, and Scholar Rock. Its competitive advantages stem from its proprietary integrin-binding molecule library, deep expertise in integrin biology, and a differentiated platform enabling tissue-specific drug delivery.
Pliant Therapeutics serves patients with serious or life-threatening diseases, particularly those with solid tumors resistant to immune checkpoint inhibitors. The company's therapeutic focus includes oncology indications such as non-small cell lung cancer, melanoma, cholangiocarcinoma, and head and neck squamous cell carcinoma. Clinical development efforts are directed toward addressing unmet medical need in these patient populations through targeted integrin inhibition strategies.